Discovery - University of Dundee - Online Publications

Library & Learning Centre

Intragenic copy number variation within filaggrin contributes to the risk of atopic dermatitis with a dose-dependent effect

Intragenic copy number variation within filaggrin contributes to the risk of atopic dermatitis with a dose-dependent effect

Research output: Contribution to journalArticle

View graph of relations

Authors

  • Sara J. Brown (Lead / Corresponding author)
  • Karin Kroboth
  • Aileen Sandilands
  • Linda E. Campbell
  • Elizabeth Pohler
  • Sanja Kezic
  • Heather J. Cordell
  • W. H. Irwin McLean
  • Alan D. Irvine

Research units

Info

Original languageEnglish
Pages98-104
Number of pages7
JournalJournal of Investigative Dermatology
Journal publication dateJan 2012
Volume132
Issue1
DOIs
StatePublished

Abstract

Loss-of-function variants within the filaggrin gene (FLG) increase the risk of atopic dermatitis. FLG also demonstrates intragenic copy number variation (CNV), with alleles encoding 10, 11, or 12 filaggrin monomers; hence, CNV may affect the amount of filaggrin expressed in the epidermis. A total of 876 Irish pediatric atopic dermatitis cases were compared with 928 population controls to test the hypothesis that CNV within FLG affects the risk of atopic dermatitis independently of FLG-null mutations. Cases and controls were screened for CNV and common FLG-null mutations. In this population the 11-repeat allele was most prevalent (allele frequency 51.5%); the 10-repeat allele frequency was 33.9% and the 12-repeat allele frequency was 14.6%. Having excluded FLG mutation carriers, the control group had a significantly higher number of repeats than cases (chi(2) P = 0.043), and the odds ratio of disease was reduced by a factor of 0.88 (95% confidence interval 0.78-0.98, P-0.025) for each additional unit of copy number. Breakdown products of filaggrin were quantified in tape-stripped stratum corneum from 31 atopic dermatitis patients and urocanic acid showed a positive correlation with total copy number. CNV within FLG makes a significant, dose-dependent contribution to atopic dermatitis risk, and therefore treatments to increase filaggrin expression may have therapeutic utility.

Documents

Library & Learning Centre

Contact | Accessibility | Policy